iX Biopharma Ltd. (SGX:42C)

Market Cap	17.67M
Revenue (ttm)	7.00M
Net Income (ttm)	-9.72M
Shares Out	883.34M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,800
Average Volume	349,635
Open	0.0200
Previous Close	0.0200
Day's Range	0.0200 - 0.0200
52-Week Range	0.0200 - 0.0570
Beta	0.76
RSI	36.45
Earnings Date	Feb 4, 2025

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 42
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 42C

Financial Performance

In 2024, iX Biopharma's revenue was 5.96 million, an increase of 0.78% compared to the previous year's 5.91 million. Losses were -10.79 million, 12.3% more than in 2023.